$2.58 Billion Apheresis Market - Global Growth, Trends, Covid-19 Impact, and Forecasts 2021-2026: Extensive Application of Plasma Therapy to Treat COVID-19 Patients - ResearchAndMarkets.com

The "Apheresis Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.

The Global Apheresis Market is valued at approximately USD 1,639 million in 2020 and is expected to witness a revenue of USD 2580 million in 2026, with a CAGR of 7.85% over the forecast period.

The Apheresis market is expected to be positively impacted during the COVID-19 pandemic owing to the extensive application of plasma therapy in the treatment of COVID-19 infected patients. Furthermore, in August 2020, the US FDA granted emergency use authorization (EUA) of convalescent plasma (CCP) therapy in hospitalized individuals with COVID-19.

Also, in April 2020, Terumo BCT Inc. and Marker Therapeutics AG received the FDA approval for the Emergency Use Authorization (EUA) of Terumo BCT's Spectra Optia Apheresis System combined with Marker Therapeutics' D2000 Adsorption Cartridge to treat patients aged 18 years or above with confirmed COVID-19 disease. Thus, given the wide usage of apheresis units in the treatment of COVID-19 patients and increasing product approvals by the FDA, the apheresis market enjoys a positive growth over the pandemic.

The propelling factors for the growth of the apheresis market include the increasing number of diseases, a rise in the demand for blood components and associated safety, technological advancement in the development of new apheresis techniques, and rise in the reimbursement policies and funding for apheresis procedures.

The use of apheresis in clinically ill patients is increasing day by day, and it has been widely used as the primary therapy or as an adjunct to other treatments for various diseases, such as thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, drug toxicities, autoimmune disease, sepsis, and fulminant hepatic failure.

Additionally, as per the Centers for Disease Control and Prevention (CDC) 2019 report, it is estimated that about 37 million (15%) adult population in the United States had chronic kidney disease (CKD). Apheresis plays a vital role in the purification of blood in patients with kidney disorders and thus drives the studied market. Along with these factors, the increasing product innovations and approvals have been driving the market growth.

For instance, in June 2020, Fresenius Kabi AG and Fresenius Kabi USA received FDA clearance for ALYX Component Collection System, which is intended for use in blood collection establishments to collect and separate whole blood into its components. Thus, owing to the aforementioned factors, the global apheresis market is expected to witness healthy growth over the forecast period.

Competitive Landscape

The market studied is moderately competitive and is dominated by a few major players, and currently, the market is well established in many areas and has shown nascent success history.

However, its full potential is yet to be determined in the developing regions. With increasing government initiatives, there is an awareness among people, which is further driving the growth of the market studied. Additional the strategic alliances and new product launches by the major companies is expected to drive market growth.

For instance, in Jan 2020, Fresenius Kabi invested EUR 30 million for the expansion of transfusion and apheresis disposables plant in Dominican Republic.

Key Topics Covered:

1 INTRODUCTION

1.1 Study Assumptions and Market Definition

1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing Global Disease Burden Resulting Rise in Demand for Blood Components and Associated Safety

4.2.2 Technological Advancement in Development of New Apheresis Techniques

4.2.3 Rise in the Reimbursement Policies and Funding for Apheresis Procedures

4.3 Market Restraints

4.3.1 High Capital Investment and Costs Associated with Apheresis Procedures

4.3.2 Shortage of Skilled Professionals

4.3.3 Risk of Blood Contamination

4.4 Porter's Five Forces Analysis

5 MARKET SEGMENTATION

5.1 By Product

5.1.1 Devices

5.1.2 Disposables

5.2 By Apheresis Procedure

5.2.1 Leukapheresis

5.2.2 Plasmapheresis

5.2.3 Plateletpheresis

5.2.4 Erythrocytapheresis

5.2.5 Other Apheresis Procedures

5.3 By Technology

5.3.1 Centrifugation

5.3.2 Membrane Separation

5.4 By Application

5.4.1 Renal Disorders

5.4.2 Hematological Disorders

5.4.3 Neurological Disorders

5.4.4 Autoimmune Disorders

5.4.5 Other Applications

5.5 Geography

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Asahi Kasei Corporation

6.1.2 B. Braun Melsungen AG

6.1.3 FRESENIUS SE & CO. KGAA (Fresenius Kabi AG)

6.1.4 Haemonetics Corporation

6.1.5 Terumo corporation (Terumo BCT)

6.1.6 Kaneka Corporation

6.1.7 Sumitomo Bakelite Company Limited (Kawasumi Laboratories Inc)

6.1.8 Medica SPA

6.1.9 Baxter International

6.1.10 Cerus Corporation

6.1.11 Nikkiso Co, Ltd

6.1.12 Macopharma SA

6.1.13 Otsuka Holdings, Co., Ltd

6.1.14 Mallinckrodt Plc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/lbj5r3

View source version on businesswire.com: https://www.businesswire.com/news/home/20210519005412/en/